GET DAILY SIGNALSCardiff Oncology (CRDF): Weighing the Path to a $6.50 Analyst Target
Key Takeaways
- The central target of $6.50 is the arithmetic mean of five verified analyst price targets reviewed for this analysis; the underlying mean is about $6.60.
- The latest verified closing price is around $0.83, implying roughly a 690% move to reach the target — a very large, high-risk proposition.
- Individual analyst targets span a wide range, from $2 to $12, reflecting sharply divided views on onvansertib's clinical and commercial prospects.
- The strongest supporting factors are positive Phase 2 (CRDF-004) data in first-line RAS-mutated mCRC, a planned move toward Phase 3, and a license settlement with Nerviano that preserved worldwide rights.
- The biggest risks are binary clinical outcomes, a modest cash runway, potential shareholder dilution from a recent offering, and several downgrades to Hold.
- Investors can find more detail on the company's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
- For broader market coverage, explore Trending AI Robots to see AI-driven trading strategies in action.
Analyst Targets and the Range of Views
The $6.50 figure is not a published consensus; it is the calculated average of five attributable analyst targets identified from recent research notes: Noble Financial's Robert LeBoyer ($12, Buy), H.C. Wainwright's Robert Burns ($9, Buy), Piper Sandler's Edward Tenthoff ($6, Overweight), Lucid Capital's Christopher Liu ($4, Buy), and Craig-Hallum ($2, Hold). The unrounded mean is about $6.60, within a wide $2-to-$12 range. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The dispersion tells the real story. Bulls emphasize onvansertib's Phase 2 efficacy and a large commercial market in mCRC, with H.C. Wainwright upgrading to Buy at $9 in September 2026 after Cardiff settled its dispute with Nerviano. Bears have retreated: Craig-Hallum cut the stock to Hold at $2 from $10 in June 2026, and both TD Cowen and William Blair moved to Hold-equivalent ratings, while Piper Sandler earlier lowered its target to $6 and pushed its assumed onvansertib approval out to 2030. Because these targets assume very different probabilities of success, the average should be read as a midpoint of opinion, not a forecast.
Current Market Position and the Road to the Target
With the shares near $0.83 and a market capitalization below $100 million, reaching $6.50 requires a gain of roughly 690% — a very large move that would essentially transform CRDF from a pre-commercial developer into a later-stage, higher-confidence biotech. The path runs through continued clinical execution: follow-up data from the CRDF-004 Phase 2 trial in first-line RAS-mutated mCRC, a clear Phase 3 design, and, over time, registration and regulatory milestones. Each step can re-rate a clinical-stage stock, but the gap between current price and target reflects the market's current skepticism about that full sequence playing out.
Factors That Could Support a Move Higher
Several verified factors could support a higher price. Onvansertib demonstrated encouraging response-rate and tolerability signals in first-line mCRC, an indication with substantial commercial potential. The September 2026 Nerviano settlement removed a legal overhang and preserved Cardiff's exclusive worldwide rights and decision-making. Positive or de-risking Phase 2 and Phase 3 data, a partnership or licensing deal, or a broader biotech risk-on environment could each compress the discount at which the stock currently trades.
Key Risks That Could Stand in the Way
The obstacles are equally clear. Cardiff ended 2025 with roughly $58.3 million in cash, funding operations only into early 2027, and the company has used a placement to raise capital, which can dilute existing holders. Clinical data can disappoint, and several analysts have already stepped back to Hold amid a delayed data readout. A small patient dataset, regulatory risk, competition in the mCRC space, and a sub-$1 share price that leaves the stock vulnerable to further declines all weigh against a move toward $6.50.
Technical Levels and Market Structure
CRDF trades in a sustained downtrend, down more than half over the past year and below both its 50-day (around $1.09) and 200-day (around $1.32) moving averages. The 52-week range spans roughly $0.76 to $3.31. In this structure, the $1.00 level and the $1.09–$1.32 zone act as overhead resistance, while the $0.76 low represents the primary support level below the current price. Any sustained move toward the target would first require reclaiming these levels and reversing the long-term decline. From what I see, reviewing recent patterns with Tickeron’s AI Pattern Search Engine adds useful context here.
Time Horizon and What to Monitor
Analyst targets for early-stage biotechs typically reflect a roughly 12-month research horizon, though firms differ, and several of the targets above were set months apart as views shifted. Investors should watch the next quarterly results, the design and initiation of the Phase 3 program, updated CRDF-004 data presentations, any additional financing activity and its dilution impact, and analyst rating or target revisions. Cash runway and the pace of clinical enrollment are the most practical near-term signals.
Final Assessment
Can Cardiff Oncology reach $6.50? The target is the average of five analyst views ranging from $2 to $12, and it sits roughly 690% above the current price — a very large move. Reaching it would require onvansertib to keep delivering positive clinical data, progress cleanly into Phase 3, and attract the financing or partnership that a $6.50 valuation implies. The principal obstacles are a limited cash runway, dilution risk, and several analysts stepping back to Hold after a delayed readout. With bulls and bears this far apart, the $6.50 figure is best understood as a high-upside scenario, not a base case, and investors should monitor the next data and financing milestones rather than treat any single target as a guarantee.
Using Tickeron’s AI Daily Buy/Sell Signals
In my research process, Tickeron’s AI Daily Buy/Sell Signals have proven useful for tracking volatile names like this one. The tool applies artificial intelligence to monitor market conditions and technical shifts, helping spot trend changes more efficiently than manual review alone. It complements my own analysis without replacing it.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CRDF in +6.02% Uptrend, advancing for three consecutive days on October 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CRDF advanced for three days, in 208 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
CRDF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRDF as a result. In 81 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for CRDF turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 31 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
CRDF moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRDF crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CRDF entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CRDF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.566) is normal, around the industry mean (3.037). P/E Ratio (-1.459) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (178.571) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors
Industry Biotechnology
Advertisement